The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and vomiting
associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and this
affects patients' quality of life and attitudes toward treatment. Although nausea and
vomiting associated with chemotherapy has been decreasing due to improved therapy, some
patients will still experience this side effect. Therefore, new medications are needed to
decrease the amount of nausea and vomiting patients have with chemotherapy. Emend
(aprepitant) is a new medication used to treat nausea and vomiting with chemotherapy, but it
has only been studied in patients receiving only one dose of chemotherapy that makes most
people sick. However, there is little experience with this medication in patients receiving
multiple days of chemotherapy that causes nausea and vomiting.
Phase:
Phase 2
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborators:
Merck Sharp & Dohme Corp. Northwestern Memorial Hospital